Protein carriers of conjugate vaccines: characteristics, development, and clinical trials
ME Pichichero - Human vaccines & immunotherapeutics, 2013 - Taylor & Francis
The immunogenicity of polysaccharides as human vaccines was enhanced by coupling to
protein carriers. Conjugation transformed the T cell-independent polysaccharide vaccines of …
protein carriers. Conjugation transformed the T cell-independent polysaccharide vaccines of …
[HTML][HTML] Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020
SA Mbaeyi - MMWR. Recommendations and Reports, 2020 - cdc.gov
This report compiles and summarizes all recommendations from CDC's Advisory Committee
on Immunization Practices (ACIP) for use of meningococcal vaccines in the United States …
on Immunization Practices (ACIP) for use of meningococcal vaccines in the United States …
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine
JL Perez, J Absalon, J Beeslaar, P Balmer… - Expert Review of …, 2018 - Taylor & Francis
Introduction: Given the characteristics of meningococcal carriage and transmission and the
sudden, often severe onset and long-term consequences of disease, vaccination can most …
sudden, often severe onset and long-term consequences of disease, vaccination can most …
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
HQ Jiang, SK Hoiseth, SL Harris, LK McNeil, D Zhu… - Vaccine, 2010 - Elsevier
Factor H binding proteins (fHBP), are bacterial surface proteins currently undergoing human
clinical trials as candidate serogroup B Neisseria meningitidis (MnB) vaccines. fHBP protein …
clinical trials as candidate serogroup B Neisseria meningitidis (MnB) vaccines. fHBP protein …
Routinely vaccinating adolescents against meningococcus: targeting transmission & disease
V Vetter, R Baxter, G Denizer, MAP Sáfadi… - Expert review of …, 2016 - Taylor & Francis
Adolescents have the highest rates of meningococcal carriage and transmission.
Interrupting the adolescent habitat in order to reduce carriage and transmission within …
Interrupting the adolescent habitat in order to reduce carriage and transmission within …
Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents
LA Jackson, R Baxter, K Reisinger… - Clinical Infectious …, 2009 - academic.oup.com
Background. Neisseria meningitidis is an important cause of invasive bacterial infection in
the United States, and disease rates are higher for adolescents than for the general …
the United States, and disease rates are higher for adolescents than for the general …
Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages
M Bröker, PM Dull, R Rappuoli, P Costantino - Vaccine, 2009 - Elsevier
Meningococcal disease is a serious medical condition that can prove fatal within hours in
otherwise healthy individuals. Disease incidence is highest in infants, yet there is no broadly …
otherwise healthy individuals. Disease incidence is highest in infants, yet there is no broadly …
Evaluation of a Group A Streptococcus synthetic oligosaccharide as vaccine candidate
A Kabanova, I Margarit, F Berti, MR Romano, G Grandi… - Vaccine, 2010 - Elsevier
Bacterial infections caused by Group A Streptococcus (GAS) are a serious health care
concern that currently cannot be prevented by vaccination. The GAS cell-wall …
concern that currently cannot be prevented by vaccination. The GAS cell-wall …
Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra
KS Reisinger, R Baxter, SL Block, J Shah… - Clinical and Vaccine …, 2009 - Am Soc Microbiol
Neisseria meningitidis is a leading cause of bacterial meningitis in the United States, with
the highest case fatality rates reported for individuals≥ 15 years of age. This study …
the highest case fatality rates reported for individuals≥ 15 years of age. This study …
[HTML][HTML] Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in≥ 56-year-olds: a phase III randomized study
A Esteves-Jaramillo, T Koehler, R Jeanfreau, D Neveu… - Vaccine, 2020 - Elsevier
Background Invasive meningococcal disease has a high mortality rate in individuals aged≥
56 years, but no vaccine is currently licensed in the USA for this age group. This study …
56 years, but no vaccine is currently licensed in the USA for this age group. This study …